![](/img/cover-not-exists.png)
Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.
McLaughlin, P, Grillo-López, A J, Link, B K, Levy, R, Czuczman, M S, Williams, M E, Heyman, M R, Bence-Bruckler, I, White, C A, Cabanillas, F, Jain, V, Ho, A D, Lister, J, Wey, K, Shen, D, Dallaire, BVolume:
16
Language:
english
Journal:
Journal of Clinical Oncology
DOI:
10.1200/jco.1998.16.8.2825
Date:
August, 1998
File:
PDF, 731 KB
english, 1998